did fda ban bpc 157 Panel Recommends Compounding Unapproved Peptides A FDA panel is weighing

Reported side effects from user communities are generally mild and infrequent

It does not create a branded finished drug, it does not trigger insurance coverage, and it does not retroactively validate marketing claims made about the compound

B.et al (1996)

Regulatory history: Sermorelin was FDA-approved in 1997 under the brand name Geref for the treatment of growth hormone deficiency in children

"Health Canada won't approve it as a drug, but it slips through as a compounded natural health product, where the federal safety check basically doesn't happen." Health Canada considers NHP compounding within a practitioner-patient relationship distinct from manufacturing and not subject to the same regulatory oversight